AS OF 12/2/22, THERE ARE NO APPROVED MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AN ACTIVE INFECTION.
PRIORITIZATION OF PATIENTS
- PRIORITY 1: UNVACCINATED AGE 65+
- PRIORITY 2: UNVACCINATED UNDER AGE 65 WITH RISK FACTORS
- PRIORITY 3: VACCINATED AGE 65+ WITH RISK FACTORS
- PRIORITY 4: VACCINATED UNDER 65 WITH MULTIPLE RISK FACTORS OR IMMUNOCOMPROMISED
ANTIBODY THERAPY APPLICATION
GVH has a limited supply of a monoclonal antibody combinations that are approved via emergency use authorization (EUA) for:
GVH stocks the following products (fact sheets are found at the bottom of this page):
These monoclonals are for outpatient use only. Applications are required to be considered for therapy.
The questionnaire below will screen for eligibility as outlined in the EUA. If a patient is eligible for therapy, you (provider) will be taken to the full application for monoclonal therapy.
To see an overview of how the entire monoclonal process goes, starting from the outpatient provider being interested all the way to the patient receiving an infusion, choose the "How Does This Whole Process Work?" button below.
After an application is submitted for an eligible patient, applications will be reviewed. Providers will be notified if their patients are selected for a monoclonal antibody treatment and which preparation the patient will receive.
Eligibility is not a guarantee of treatment.
- Mild to moderate COVID-19 in adult patients and some pediatric patients
- Post-exposure prophylaxis in individuals who are at high risk for progression to severe COVID-19
GVH stocks the following products (fact sheets are found at the bottom of this page):
- Sotrovimab (GSK)
- Casirivimab / imdevimab (Regeneron)
- Bamlanivimab / etesevimab (Eli Lilly)
- Bebtelovimab (Eli Lilly)
These monoclonals are for outpatient use only. Applications are required to be considered for therapy.
The questionnaire below will screen for eligibility as outlined in the EUA. If a patient is eligible for therapy, you (provider) will be taken to the full application for monoclonal therapy.
To see an overview of how the entire monoclonal process goes, starting from the outpatient provider being interested all the way to the patient receiving an infusion, choose the "How Does This Whole Process Work?" button below.
After an application is submitted for an eligible patient, applications will be reviewed. Providers will be notified if their patients are selected for a monoclonal antibody treatment and which preparation the patient will receive.
Eligibility is not a guarantee of treatment.